Amylyx Pharmaceuticals Inc (AMLX)vsTeva Pharma Industries Ltd ADR (TEVA)
AMLX
Amylyx Pharmaceuticals Inc
$29.86
-6.10%
HEALTHCARE · Cap: $4.09B
TEVA
Teva Pharma Industries Ltd ADR
$43.24
+0.95%
HEALTHCARE · Cap: $50.14B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates -2591077% more annual revenue ($17.23B vs $-665,000). TEVA leads profitability with a 2.9% profit margin vs 0.0%. TEVA earns a higher WallStSmart Score of 42/100 (D).
AMLX
Avoid33
out of 100
Grade: F
TEVA
Hold42
out of 100
Grade: D
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Strong operational efficiency at 27.4%
Areas to Watch
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
ROE of 6.3% — below average capital efficiency
2.9% margin — thin
Premium valuation, high expectations priced in
Revenue declined 1.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : AMLX
The strongest argument for AMLX centers on Debt/Equity, Altman Z-Score.
Bull Case : TEVA
The strongest argument for TEVA centers on Market Cap, Operating Margin. PEG of 1.04 suggests the stock is reasonably priced for its growth.
Bear Case : AMLX
The primary concerns for AMLX are EPS Growth, Profit Margin, Operating Margin.
Bear Case : TEVA
The primary concerns for TEVA are Return on Equity, Profit Margin, P/E Ratio. A P/E of 99.9x leaves little room for execution misses. Debt-to-equity of 2.13 is elevated, increasing financial risk.
Key Dynamics to Monitor
TEVA carries more volatility with a beta of 0.84 — expect wider price swings.
TEVA is growing revenue faster at -1.9% — sustainability is the question.
TEVA generates stronger free cash flow (121M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
TEVA scores higher overall (42/100 vs 33/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amylyx Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Amylyx Pharmaceuticals Inc (AMLX) is an innovative biopharmaceutical company at the forefront of developing transformative therapies for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). The company's lead candidate, AMX0035, employs a unique neuroprotective mechanism that has shown significant potential in improving patient outcomes in clinical trials. With a robust pipeline and a dedicated team of neurology experts, Amylyx is well-positioned to tackle substantial unmet medical needs in the neurodegenerative space, making it an attractive investment opportunity for institutional investors seeking to support advancements in critical healthcare solutions.
Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?